Preface
Translational approaches to investigation of solid tumor malignancies: shifting landscapes, smarter strategies and tactics for therapeutic design, improving patient outcomes
Annals of Translational Medicine
2018;
6
(9)
:158
.
(15 May 2018)
Review Article
Colorectal cancer genomics and designing rational trials
Annals of Translational Medicine
2018;
6
(9)
:159
.
(15 May 2018)
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment
Annals of Translational Medicine
2018;
6
(9)
:160
.
(15 May 2018)
Prostate cancer in the era of “Omic” medicine: recognizing the importance of DNA damage repair pathways
Annals of Translational Medicine
2018;
6
(9)
:161
.
(15 May 2018)
Original Article
Optimization of a microfluidics-based next generation sequencing assay for clinical oncology diagnostics
Annals of Translational Medicine
2018;
6
(9)
:162
.
(15 May 2018)
Review Article
Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies
Annals of Translational Medicine
2018;
6
(9)
:163
.
(15 May 2018)
Translational research and application of basic biology to clinical trial development in GI cancers
Annals of Translational Medicine
2018;
6
(9)
:164
.
(15 May 2018)
Original Article
Survival outcomes for advanced kidney cancer patients in the era of targeted therapies
Annals of Translational Medicine
2018;
6
(9)
:165
.
(15 May 2018)
Review Article
Financial toxicity and implications for cancer care in the era of molecular and immune therapies
Annals of Translational Medicine
2018;
6
(9)
:166
.
(15 May 2018)
Perspective
Transforming research: engaging patient advocates at all stages of cancer research
Annals of Translational Medicine
2018;
6
(9)
:167
.
(15 May 2018)
Editorial
The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy
Annals of Translational Medicine
2018;
6
(9)
:168
.
(15 May 2018)
Disclosure:
The focused issue “Translational approach to investigation of solid tumor malignancies” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Emil Lou served as the unpaid Guest Editor for the focused issue.